Salute e Benessere

Joint Reconstruction Devices Market Reach US$ 30,573.75 Million by 2033 at CAGR…

Check valuable insights in the Joint Reconstruction Devices Market report. You can easily get a sample PDF of the report - https://www.businessmarketinsights.com/sample/BMIPUB00031715 Check valuable insights in theJoint Reconstruction Devices Market report.You can easily get a sample PDF of the report -https://www.businessmarketinsights.com/sample/BMIPUB00031715 Advancements in implant technology and surgery are playing a crucial role in shaping the joint reconstruction devices market...
PR Newswire
30/09/2025

Peritoneal Dialysis Equipment Market to Reach US$4.09 Billion by 2031 at 6.6%…

Governments in developing regions have proactively developed the peritoneal dialysis market by focusing on access, affordability, and sustainability. A major component of this will be "PD-first" or "PD-favored" policies that will dictate that PD should be the first and preferred treatment modality for clinically appropriate patients. The costs of care associated with PD are lower than those of in-center hemodialysis (HD) because PD does not require expensive infrastructure…
PR Newswire
30/09/2025

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target…

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. Estimated cash runway for combined company extends through 2027.Transaction projected to close in...
Nasdaq GlobeNewswire
30/09/2025

Navinci Launches Naveni® Plex Omni Service Providing Expert-Led Access to…

This technology can be used to uncover complex biological processes such as tumor-stroma crosstalk, immune cell functional states, and molecular mechanisms that influence treatment responses - including why some cancers evade immune detection and why patients respond differently to immunotherapy. This technology can be used to uncover complex biological processes such as tumor-stroma crosstalk, immune cell functional states, and molecular mechanisms that influence treatment responses -...
PR Newswire
30/09/2025

Elton John AIDS Foundation expands The Rocket Fund to $200 million

"I established the Foundation when the end of AIDS seemed impossible — many would not even say the word. Resources were scarce, but many brave, passionate people made the world take notice," said Elton John, Founder of the Elton John AIDS Foundation. "Today, we stand together on the brink of ending this epidemic, and we won't waste that opportunity. We are doubling down and extending the goal of our Rocket Fund to $200 million to make sure we continue to fuel the momentum that…
PR Newswire
30/09/2025

Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce…

Why Inflammation Detection Matters "Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease," said Dr.Michael Doney, Executive Medical Director of Biograph . "By engaging in such a partnership with Caristo, we're better suited to position our members at the forefront of cardiac diagnostics, providing research access to a technology not yet broadly available in the U.S." Current clinical pathways...
PR Newswire
30/09/2025

Coloplast A/S - Financial Calendar 2025-26

Please see enclosed pdf.For more information and calendar invitations for upcoming events, please visit: https://www.coloplast.com/investor-relations/events-calendar/ Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 For further information, please contactInvestors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111Kristine Husted Munk Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email:...
Nasdaq GlobeNewswire
30/09/2025

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh,...
Nasdaq GlobeNewswire
30/09/2025

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide…

Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 --VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target ofVoyager Acquisition Corp.(NASDAQ:VACH, “Voyager”), andSecarna Pharmaceuticals GmbH & Co. KG, a company redefining the...
Nasdaq GlobeNewswire
30/09/2025

Kexing Biopharm's Sorafenib Generic Receives Approvals in Egypt and Peru

Sorafenib, as a well-recognized molecular targeted therapy, is indicated for the treatment of some kind of cancers. With these back-to-back approvals, Kexing Biopharm has further expanded the geographic reach of Sorafenib, enhancing its accessibility across both the Middle East & North Africa (MENA) region and Latin America, where the demand for oncology medicines continues to grow. Sorafenib, as a well-recognized molecular targeted therapy, is indicated for the treatment of some kind of…
PR Newswire
30/09/2025

Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium…

Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare today announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray’s EU‑GMP certified facility in Neumünster as part of the BfArM in‑country cultivation program. The...
Nasdaq GlobeNewswire
30/09/2025

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal 

ORION CORPORATION PRESS RELEASE30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia.ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized. Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the...
Nasdaq GlobeNewswire
30/09/2025

Restoring children's vision, reducing inequalities: NTC renews partnership with…

"Removing cataracts in children is an act of social as well as health justice," said Riccardo Carbucicchio, CEO of NTC. "This is why our collaboration with Sightsavers Italia is a source of particular pride for us: it represents a concrete step in our commitment to the United Nations Sustainable Development Goals, in particular SDG 10, which promotes the reduction of inequalities. Sight should not be a privilege, but a right accessible to everyone, everywhere in the world."…
PR Newswire
30/09/2025

Cozy Up Your Home This Fall with Waterdrop Filter's Prime Day Deals

Featured Prime Day Offers (October 7th-8th): Featured Prime Day Offers ( October 7th-8th ): Waterdrop X12 RO System: MSRP £1,299 → £999 (23% off) .Its 11-stage filtration and 1200 GPD high-speed performance ensure your kitchen gets pristine, great-tasting water instantly. Waterdrop G5P700A RO System: MSRP £349.99 → £279.99 (20% off). This advanced RO system offers an 8-stage filtration process, removing contaminants while adding essential minerals for a balanced, alkaline...
PR Newswire
30/09/2025

Data4Life and EvidNet form strategic partnership to advance federated real-world…

Global health research, locally enabled Global health research, locally enabled At the core of the collaboration is the integration ofEvidNet's FeederNetnetwork—comprising over50 hospitals and 70 million patient records —withData4Life's open-source research platform Data2Evidence. By aligning on international standards such asOMOPandFHIR, the partners aim to provide researchers worldwide with access to fit-for-purpose real-world data, ready for scientific and regulatory use...
PR Newswire
30/09/2025

Karo Healthcare appoints Konstanze Gallinatus as Chief Transformation Officer

"We are excited to welcome Konstanze to Karo. With her strong leadership capabilities and track record in transformation, execution, and value creation in a private equity context, she will be instrumental in Karo's next growth journey with KKR and the realization of our value creation plan. Subject to regulatory approvals, Konstanze will also take a key role in supporting the future integration of the Perrigo Skin Health business. I very much look forward to working with her," says…
PR Newswire
30/09/2025

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an…

Over the past year, Merus' lead program petosemtamab, has delivered best-in-class Phase 2 results in both first-line and later-line head and neck cancer, significantly outperforming historical benchmarks and positioning itself as a potential standard-of-care redefining therapy. In addition, Phase 2 trials are ongoing in colorectal cancer in first-, second- and third-line settings. With two FDA Breakthrough Therapy Designations, petosemtamab is well positioned to transform outcomes in head and…
PR Newswire
30/09/2025

Epigenica AB Launches the Groundbreaking EpiFinder™ GenomePro - Unlocking the…

EpiFinder™ GenomePro, the next-gen version of the EpiFinder™ Genome, features optimized reagents and shorter protocols for analyzing 24 samples in a single run. With EpiFinder™ GenomePro, researchers obtain robust quantitative data for 192 genome-wide Chromatin Immunoprecipitation Sequencing (ChIP-Seq) profiles for multiple hPTMs and DNA methylation from minimal sample volumes. The reduced cost per sample is a key advantage, making large-scale studies more accessible than ever...
PR Newswire
30/09/2025

New number of shares and votes in Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Sobi is a global biopharma company unlocking the potential of breakthrough innovations,...
PR Newswire
30/09/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 30 September 2025 at 9.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 26...
Nasdaq GlobeNewswire
30/09/2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at…

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025Schlieren (Zürich), Switzerland – September 30, 2025– Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros...
Nasdaq GlobeNewswire
30/09/2025

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya…

Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunyaSaint-Herblain (France), September 30, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ ®...
Nasdaq GlobeNewswire
30/09/2025

Data show Roche’s sixth-generation Troponin T test offers a new level of…

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring patients receive the care they need at the earliest opportunity.The global TSIX clinical study involved more than 13,000 participants, validating performance across a diverse population that reflects real-world healthcare settings. 1,2 Basel, 30...
Nasdaq GlobeNewswire
30/09/2025

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results…

Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully throughIND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming...
Nasdaq GlobeNewswire
30/09/2025
Altri  Comunicati